Premium
Developing Pharmacogenetic Evidence Throughout Clinical Development
Author(s) -
Burns D K
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.246
Subject(s) - pharmacogenetics , drug development , personalized medicine , pharmaceutical industry , clinical practice , medicine , precision medicine , engineering ethics , drug , risk analysis (engineering) , intensive care medicine , pharmacology , bioinformatics , biology , family medicine , genetics , engineering , genotype , pathology , gene
Genetics as a discipline is fundamental for the pharmaceutical industry; it contributes to all therapeutic areas and has an impact throughout the research and development continuum, right up to and including clinical practice. Pharmacogenetics is seen as a significant contributor to increasing the efficiency and effectiveness of pharmaceutical R&D, and it enhances the growing interest in personalized medicine. This article discusses some contemporary issues that influence drug development and examines the potential of pharmacogenetics to reduce the risk and uncertainty that are inherent in the drug development process. Clinical Pharmacology & Therapeutics (2010) 88 6, 867–870. doi: 10.1038/clpt.2010.246